Showing $8.83 netcash remaining after the executives raided-the-till heavily this quarter. Still my favorite play - added at 8.02 at the open - many catalysts working here:
Expected Milestones
Present final results for all subjects from the MarzAA Phase 2 open-label SQ efficacy trial at the ISTH meeting in July 2019; initiate a MarzAA Phase 1 pharmacokinetic and pharmacodynamic study in Q2 2019 with final data read out in Q4 2019; and request an End of Phase 2 meeting with the FDA by the end of 2019.
Complete the DalcA Phase 2b open-label SQ long-term dosing study, with final data readout in Q4 2019.
News 
Market Data 
Discover 
